Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HLX208 plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer
CTR20211690Phase 2Completed
- Sponsor
- Suzhou Runxin Biotechnology
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HLX208, cetuximab in colorectal cancer (CRC), sponsored by Suzhou Runxin Biotechnology. Started Aug 2021; status: completed.
02
Drugs
HLX208cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20211690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211690.